Extended Data Fig. 8: Growth advantage of TP53 mutations identified from TISCC-seq in HCT116 cells confirmed by CRISPR base editing and nutlin-3a treatment. | Nature Biotechnology

Extended Data Fig. 8: Growth advantage of TP53 mutations identified from TISCC-seq in HCT116 cells confirmed by CRISPR base editing and nutlin-3a treatment.

From: Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells

Extended Data Fig. 8

We introduced various TP53 mutations to HCT116 cells using CRISPR base editors and subsequently cultured the cells under media containing nutlin-3a. Analysis of the resulting population revealed an increasing frequency of the introduced mutations, indicating a growth advantage for cells with TP53 mutations compared to wild-type cells. These results provide evidence for the selective advantage conferred by TP53 mutations in HCT116 cells. N = 3 biologically independent cells for C135Y and N = 2 biologically independent cells for others. P = 0.00352, 0.0417, 0.161, 0.0786, 0.109, 0.00165, 0.064, 0.0287, 0.00885, 0.00189; two-sided t-test.

Back to article page